Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history

Fig. 1

Lung function difference versus BGFa, b: EOS subgroups by exacerbation history or COPD severity, mITT population. aChange from baseline in morning pre-dose trough FEV1 over 12–24 weeks. bFrom a linear repeated measures model which included the following covariates: baseline FEV1, percent reversibility to salbutamol, and baseline EOS count as continuous covariates and visit, treatment, treatment-by-visit interaction, and ICS use at screening (yes/no) as categorical covariates. Abbreviations: BFF: budesonide/formoterol fumarate dihydrate; BGF: budesonide/glycopyrronium/formoterol fumarate dihydrate; CI: confidence interval; COPD: chronic obstructive pulmonary disease; EOS: eosinophil; FEV1: forced expiratory volume in 1 s; GFF: glycopyrronium/formoterol fumarate dihydrate; ICS: inhaled corticosteroid; LS: least squares; mITT: modified intention-to-treat

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us